Platform for Plasmodium vivax vaccine discovery and development

Memorias do Instituto Oswaldo Cruz

Volumn 106, Issue SUPPL. 1, 2011, Pages 179-192

  Valencia, Sócrates Herrera ^a,b,c   Rodríguez, Diana Carolina ^a,b   Acero, Diana Lucía ^a,b   Ocampo, Vanessa ^a,b   Arévalo Herrera, Myriam ^a,b,c  

^a Caucaseco Scientific Research Centre   (Colombia)

^b Centro Latino Americano de Investigacion en Malaria   (Colombia)

^c UNIVERSIDAD DEL VALLE   (Colombia)

Author keywords

Discovery; Latin america; Malaria; Neglected disease; Plasmodium vivax; Vaccine development; Vaccine platform

Indexed keywords

CELL SURFACE RECEPTOR; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; DUFFY ANTIGEN BINDING PROTEIN, PLASMODIUM; MALARIA VACCINE; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ANIMAL; ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOLOGY; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; SOUTH AND CENTRAL AMERICA;

ANIMALS; ANTIGENS, PROTOZOAN; CLINICAL TRIALS AS TOPIC; HUMANS; LATIN AMERICA; MALARIA VACCINES; MALARIA, VIVAX; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECEPTORS, CELL SURFACE;

PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

EID: 80051734266     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762011000900023     Document Type: Article

References (176)

1. Acharya P, Pallavi R, Chandran S, Chakravarti H, Middha S, Acharya J, Kochar S, Kochar D, Subudhi A, Boopathi AP, Garg S, Das A, Tatu U 2009. A glimpse into the clinical proteome of human malaria parasites Plasmodium falciparum and Plasmodium vivax. Proteomics Clin Appl 3: 1314-1325.
2. Aide P, Dobaño C, Sacarlal J, Aponte JJ, Mandomando I, Guinovart C, Bassat Q, Renom M, Puyol L, Macete E, Herreros E, Leach A, Dubois MC, Demoitie MA, Lievens M, Vekemans J, Loucq C, Ballou WR, Cohen J, Alonso PL 2011. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine: doi: 10.1016/j.vaccine.2011.03.041.
3. Alonso L, Brown G, Arévalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine M, Mendis K, Newman R, Plowe C, Rodríguez M, Sinden R, Slutsker L, Tanner M 2011. A research agenda to underpin malaria eradication. PLoS Medicine 8: e1000406.
4. Alves FA, Souza MT, Goncalves EC, Schneider MP, Marinho AM, Muniz JA, Fragoso SP, Krieger MA, Goldenberg S, Daniel-Ribeiro CT, Carvalho LJ 2010. DNA sequencing of 13 cytokine gene fragments of Aotus infulatus and Saimiri sciureus, two non-human primate models for malaria. Cytokine 52: 151-155.
5. Alves FP, Gil LH, Marrelli MT, Ribolla PE, Camargo EP, Da Silva LH 2005. Asymptomatic carriers of Plasmodium spp as infection source for malaria vector mosquitoes in the Brazilian Amazon. J Med Entomol 42: 777-779.
6. Andrade MC, Ribeiro CT, Silva VF, Molinaro EM, Gonçalves MA, Marques MA, Cabello PH, Leite JP 2004. Biologic data of Macaca mulatta, Macaca fascicularis and Saimiri sciureus used for research at the Fiocruz Primate Center. Mem Inst Oswaldo Cruz 99: 581-589.
7. Ansari FA, Kumar N, Bala Subramanyam M, Gnanamani M, Ramachandran S 2008. MAAP: malarial adhesins and adhesin-like proteins predictor. Proteins 70: 659-666.
8. Arévalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R, Herrera S 2005a. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am J Trop Med Hyg 73: 25-31.
9. Arévalo-Herrera M, Chitnis C, Herrera S 2010. Current status of Plasmodium vivax vaccine. Hum Vaccin 6: 124-132.
10. Arévalo-Herrera M, Roggero MA, González JM, Vergara J, Corradin G, Lopez JA, Herrera S 1998. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. Ann Trop Med Parasitol 92: 539-551.
11. Arévalo-Herrera M, Solarte Y, Rocha L, Alvarez D, Beier JC, Herrera S 2011a. Characterization of Plasmodium vivax transmission-blocking activity in low to moderate malaria transmission settings of the Colombian Pacific coast. Am J Trop Med Hyg 84: 71-77.
12. Arévalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincón A, Saul A, Mu J, Long C, Miller L, Herrera S 2005b. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. Am J Trop Med Hyg 73 (Suppl. 5): 32-37.
13. Arévalo-Herrera M, Solarte Y, Zamora F, Mendez F, Yasnot M, Rocha L, Long C, Miller L, Herrera S 2005c. Plasmodium vivax: transmission-blocking immunity in a malaria-endemic area of Colombia. Am J Trop Med Hyg 73: 38-43.
14. Arévalo-Herrera M, Valencia AZ, Vergara J, Bonelo A, Fleischhauer K, González JM, Restrepo JC, Lopez JA, Valmori D, Corradin G, Herrera S 2002. Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite Immunol 24: 161-169.
15. Arévalo-Herrera M, Vera O, Castellanos A, Cespedes N, Soto L, Corradin G, Herrera S 2011b. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants. Am J Trop Med Hyg 84: 21-27.
16. Arnot DE, Barnwell JW, Tam JP, Nussenzweig V, Nussenzweig RS, Enea V 1985. Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science 230: 815-818.
17. Arruda ME, Zimmerman RH, Souza RM, Oliveira-Ferreira J 2007. Prevalence and level of antibodies to the circumsporozoite protein of human malaria parasites in five states of the Amazon region of Brazil. Mem Inst Oswaldo Cruz 102: 367-371.
18. Aurrecoechea C, Brestelli J, Brunk BP, Dommer J, Fischer S, Gajria B, Gao X, Gingle A, Grant G, Harb OS, Heiges M, Innamorato F, Iodice J, Kissinger JC, Kraemer E, Li W, Miller JA, Nayak V, Pennington C, Pinney DF, Roos DS, Ross C, Stoeckert CJ Jr, Treatman C, Wang H 2009. PlasmoDB: a functional genomic database for malaria parasites. Nucleic Acids Res 37: D539-543.
19. Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM 2010. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium. Vaccine 28: 2818-2826.
20. Bastos MS, da Silva-Nunes M, Malafronte RS, Hoffmann EH, Wunderlich G, Moraes SL, Ferreira MU 2007. Antigenic polymorphism and naturally acquired antibodies to Plasmodium vivax merozoite surface protein 1 in rural Amazonians. Clin Vaccine Immunol 14: 1249-1259.
21. Bell BA, Wood JF, Bansal R, Ragab H, Cargo Jr, Washington MA, Wood CL, Ware LA, Ockenhouse CF, Yadava A 2009. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine 27: 1448-1453.
22. BenMohamed L, Thomas A, Druilhe P 2004. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infect Immun 72: 4376-4384.
23. Bottius E, Guanzirolli A, Trape JF, Rogier C, Konate L, Druilhe P 1996. Malaria: even more chronic in nature than previously thought; evidence for subpatent parasitaemia detectable by the polymerase chain reaction. Trans R Soc Trop Med Hyg 90: 15-19.
24. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P 1995. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182: 409-418.
25. Bozdech Z, Mok S, Hu G, Imwong M, Jaidee A, Russell B, Ginsburg H, Nosten F, Day NP, White NJ, Carlton JM, Preiser PR 2008. The transcriptome of Plasmodium vivax reveals divergence and diversity of transcriptional regulation in malaria parasites. Proc Natl Acad Sci USA 105: 16290-16295.
26. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, Crabtree J, Angiuoli SV, Merino EF, Amedeo P, Cheng Q, Coulson RM, Crabb BS, Del Portillo HA, Essien K, Feldblyum TV, Fernandez-Becerra C, Gilson PR, Gueye AH, Guo X, Kang'a S, Kooij TW, Korsinczky M, Meyer EV, Nene V, Paulsen I, White O, Ralph SA, Ren Q, Sargeant TJ, Salzberg SL, Stoeckert CJ, Sullivan SA, Yamamoto MM, Hoffman SL, Wortman JR, Gardner MJ, Galinski MR, Barnwell JW, Fraser-Liggett CM 2008. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 455: 757-763.
27. Carter R, Mendis KN, Miller LH, Molineaux L, Saul A 2000. Malaria transmission-blocking vaccines-how can their development be supported? Nat Med 6: 241-244.
28. Carvalho LJ, Alves FA, Bianco C, Jr., Oliveira SG, Zanini GM, Soe S, Druilhe P, Theisen M, Muniz JA, Daniel-Ribeiro CT 2005. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA 720 adjuvants. Clin Diagn Lab Immunol 12: 242-248.
29. Carvalho LJ, Oliveira SG, Alves FA, Brígido MC, Muniz JA, Daniel-Ribeiro CT 2000. Aotus infulatus monkey is susceptible to Plasmodium falciparum infection and may constitute an alternative experimental model for malaria. Mem Inst Oswaldo Cruz 95: 363-365.
30. Carvalho LJ, Oliveira SG, Theisen M, Alves FA, Andrade MC, Zanini GM, Brigido MC, Oeuvray C, Povoa MM, Muniz JA, Druilhe P, Daniel-Ribeiro CT 2004. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J Immunol 59: 363-372.
31. Castellanos A, Arévalo-Herrera M, Restrepo N, Gulloso L, Corradin G, Herrera S 2007. Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys. Mem Inst Oswaldo Cruz 102: 411-416.
32. Ceravolo IP, Sanchez BA, Sousa TN, Guerra BM, Soares IS, Braga EM, McHenry AM, Adams JH, Brito CF, Carvalho LH 2009. Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection. Clin Exp Immunol 156: 502-510.
33. Chitnis CE, Miller LH 1994. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 180: 497-506.
34. Chitnis CE, Sharma A 2008. Targeting the Plasmodium vivax Duffy-binding protein. Trends Parasitol 24: 29-34.
35. Clyde DF 1990. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. Bull World Health Organ 68: 9-12.
36. Cohen S 1979. Immunity to malaria. Proc R Soc Lond B Biol Sci 203: 323-345.
37. Cohen S, McGregor IA, Carrington S 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192: 733-737.
38. Cole-Tobian JL, Michon P, Biasor M, Richards JS, Beeson JG, Mueller I, King CL 2009. Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous Plasmodium vivax strains in Papua New Guinean children. Infect Immun 77: 4009-4017.
39. Collins WE 1990. Testing of Plasmodium vivax CS proteins in Saimiri monkeys. Bull World Health Organ 68: 42-46.
40. Collins WE 1992. South American monkeys in the development and testing of malarial vaccines - A review. Mem Inst Oswaldo Cruz 87 (Suppl. III): 401-406.
41. Collins WE, Jeffery GM 1999. A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Am J Trop Med Hyg 61: 20-35.
42. Collins WE, Jeffery GM, Roberts JM 2004. A retrospective examination of reinfection of humans with Plasmodium vivax. Am J Trop Med Hyg 70: 642-644.
43. Collins WE, McClure HM, Swenson RB, Mehaffey PC, Skinner JC 1986. Infection of mosquitoes with Plasmodium vivax from chimpanzees using membrane feeding. Am J Trop Med Hyg 35: 56-60.
44. Corradin G, Kajava AV, Verdini A 2010. Long synthetic peptides for the production of vaccines and drugs: a technological platform coming of age. Sci Transl Med 2: 50rv3.
45. Coura JR, Suárez-Mutis M, Ladeia-Andrade S 2006. A new challenge for malaria control in Brazil: asymptomatic Plasmodium infection - A review. Mem Inst Oswaldo Cruz 101: 229-237.
46. Crompton PD, Pierce SK, Miller LH 2010. Advances and challenges in malaria vaccine development. J Clin Invest 120: 4168-4178.
47. Cucunubá ZM, Guerra AP, Rahirant SJ, Rivera JA, Cortés LJ, Ni-cholls RS 2008. Asymptomatic Plasmodium spp infection in Tierralta, Colombia. Mem Inst Oswaldo Cruz 103: 668-673.
48. Cunningham D, Lawton J, Jarra W, Preiser P, Langhorne J 2010. The pir multigene family of Plasmodium: antigenic variation and beyond. Mol Biochem Parasitol 170: 65-73.
49. Curado I, Duarte AM, Lal AA, Oliveira SG, Kloetzel JK 1997. Antibodies anti bloodstream and circumsporozoite antigens (Plasmodium vivax and Plasmodium malariae/P. brasilianum) in areas of very low malaria endemicity in Brazil. Mem Inst Oswaldo Cruz 92: 235-243.
50. Das A, Sharma M, Gupta B, Dash AP 2009. Plasmodium falciparum and Plasmodium vivax: so similar, yet very different. Parasitol Res 105: 1169-1171.
51. Day KP, Marsh K 1991. Naturally acquired immunity to Plasmodium falciparum. Immunol Today 12: A68-71.
52. Del Portillo HA, Longacre S, Khouri E, David PH 1991. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species. Proc Natl Acad Sci USA 88: 4030-4034.
53. Dharia NV, Bright AT, Westenberger SJ, Barnes SW, Batalov S, Kuhen K, Borboa R, Federe GC, McClean CM, Vinetz JM, Neyra V, Llanos-Cuentas A, Barnwell JW, Walker JR, Winzeler EA 2010. Whole-genome sequencing and microarray analysis of ex vivo Plasmodium vivax reveal selective pressure on putative drug resistance genes. Proc Natl Acad Sci USA 107: 20045-20050.
54. Diallo M, Toure AM, Traore SF, Niare O, Kassambara L, Konare A, Coulibaly M, Bagayogo M, Beier JC, Sakai RK, Toure YT, Doumbo OK 2008. Evaluation and optimization of membrane feeding compared to direct feeding as an assay for infectivity. Malar J 7: 248.
55. Dinglasan RR, Jacobs-Lorena M 2008. Flipping the paradigm on malaria transmission-blocking vaccines. Trends Parasitol 24: 364-370.
56. Dinglasan RR, Kalume DE, Kanzok SM, Ghosh AK, Muratova O, Pandey A, Jacobs-Lorena M 2007. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc Natl Acad Sci USA 104: 13461-13466.
57. Doolan DL, Dobaño C, Baird JK 2009. Acquired immunity to malaria. Clinical Microbiology Reviews 22: 13-36.
58. Fang XD, Kaslow DC, Adams JH, Miller LH 1991. Cloning of the Plasmodium vivax Duffy receptor. Mol Biochem Parasitol 44: 125-132.
59. Feachem RGA, Phillips AA, Targett GA 2009. Shrinking the malaria map: a prospectus on malaria elimination, The Global Health Group, San Francisco. Available from: www.map.ox.ac.uk/PDF/MEG_prospectus.pdf.
60. Foth BJ, Zhang N, Chaal BK, Sze SK, Preiser PR, Bozdech Z. 2011. Quantitative time-course profiling of parasite and host cell proteins in the human malaria parasite Plasmodium falciparum. Mol Cell Proteomics: doi: 10.1074.
61. Gabaldon A 1983. Malaria eradication in Venezuela: doctrine, practice and achievement after twenty years. Am J Trop Med Hyg 32: 203-211.
62. Gabaldon A, Berti LA, Guerrero L, Garcia Martin G 1961. Eradication of malaria in Venezuela. Program, progress and present status. Rev Sanid Asist Soc (Suppl. 3): 290-336.
63. Galinski MR, Medina CC, Ingravallo P, Barnwell JW 1992. A reticulocyte-binding protein complex of Plasmodium vivax merozoites. Cell 69: 1213-1226.
64. Gamage-Mendis AC, Rajakaruna J, Weerasinghe S, Mendis C, Carter R, Mendis KN 1993. Infectivity of Plasmodium vivax and P. falciparum to Anopheles tessellatus; relationship between oocyst and sporozoite development. Trans R Soc Trop Med Hyg 87: 3-6.
65. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B 2002. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419: 498-511.
66. Girard MP, Reedb ZH, Friede M, Kieny MP 2007. A review of human vaccine research and development: malaria. Vaccine 25: 1567-1580.
67. González JM, Hurtado S, Arévalo-Herrera M, Herrera S 2001. Variants of the Plasmodium vivax circumsporozoite protein (VK210 and VK247) in Colombian isolates. Mem Inst Oswaldo Cruz 96: 709-712.
68. González JM, Olano V, Vergara J, Arévalo-Herrera M, Carrasquilla G, Herrera S, Lopez JA 1997. Unstable, low-level transmission of malaria on the Colombian Pacific coast. Ann Trop Med Parasitol 91: 349-358.
69. Good MF, Doolan DL 2010. Malaria vaccine design: immunological considerations. Immunity 33: 555-566.
70. Goodman AL, Draper SJ 2010. Blood-stage malaria vaccines - recent progress and future challenges. Ann Trop Med Parasitol 104: 189-211.
71. Gozalo A, Montoya E 1990. Reproduction of the owl monkey (Aotus nancymai) (primates: Cebidae) in captivity. Am J Primatol 21: 61-68.
72. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI, Snow RW 2008. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Medicine 5: e38.
73. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IRF, Baird JK, Snow RW, Hay SI 2010. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis 4: e774.
74. Gusmão R 1999. Overview of malaria control in the Americas. Parassitologia 41: 355-360.
75. Hafalla JC, Silvie O, Matuschewski K 2011. Cell biology and immunology of malaria. Immunol Rev 240: 297-316.
76. Healer J, Mcguinness D, Hopcroft P, Haley S, Carter R, Riley E 1997. Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Infect Immun 65: 3017-3023.
77. Herrera S 2005. La malaria: estrategias actuales para el desarrollo de una vacuna efectiva. Rev Acad Colomb Cienc 29: 535-546.
78. Herrera S, Bonelo A, Perlaza BL, Fernández OL, Victoria L, Lenis AM, Soto L, Hurtado H, Acuña LM, Vélez JD, Palacios R, Chen-Mok M, Corradin G, Arévalo-Herrera M 2005a. Safety and elicitation of humoral and cellular responses in colombian malaria-naïve volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 73: 3-9.
79. Herrera S, Bonelo A, Perlaza BL, Valencia AZ, Cifuentes C, Hurtado S, Quintero G, López JA, Corradin G, Arévalo-Herrera M 2004. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int J Parasitol 34: 1535-1546.
80. Herrera S, Corradin G, Arévalo-Herrera M 2007. An update on the search for a Plasmodium vivax vaccine. Trends Parasitol 23: 122-128.
81. Herrera S, De Plata C, Gonzalez M, Perlaza BL, Bettens F, Corradin G, Arévalo-Herrera M 1997. Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys. Parasite Immunol 19: 161-170.
82. Herrera S, Escobar P, de Plata C, Avila GI, Corradin G, Herrera MA 1992. Human recognition of T cell epitopes on the Plasmodium vivax circumsporozoite protein. J Immunol 148: 3986-3990.
83. Herrera S, Fernández O, Manzano MR, Murrain B, Vergara J, Blanco P, Palacios R, Vélez JD, Epstein JE, Chen-Mok M, Reed ZH, Arévalo-Herrera M 2009. Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am J Trop Med Hyg 81: 740-746.
84. Herrera S, Fernández OL, Vera O, Cardenas W, Ramirez O, Palacios R, Chen-Mok M, Corradin G, Arévalo-Herrera M 2011. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am J Trop Med Hyg 84: 12-20.
85. Herrera S, Gómez A, Vera O, Vergara J, Valderrama-Aguirre A, Maestre A, Méndez F, Wang R, Chitnis CE, Yazdani SS, Arévalo-Herrera M 2005b. Antibody response to Plasmodium vivax antigens in Fy-negative individuals from the Colombian Pacific coast. Am J Trop Med Hyg 73: 44-49.
86. Herrera S, Perlaza BL, Bonelo A, Arévalo-Herrera M 2002. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. Int J Parasitol 32: 1625-1635.
87. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Chattopadhyay R, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV, Sim BK 2010. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6: 97-106.
88. Hoffman SL, Fracke DE, Hollingdale MR, Druilhe P 1996. Attacking the infected hepatocyte. In S Hoffman, Malaria vaccine development: a multi-immune response approach, ASM Press, Washington, p. 35.
89. Hoffman SL, Miller L 1996. Perspectives on malaria vaccine development. In S Hoffman, Malaria vaccine development, ASM Press, Washington, p. 1-13.
90. Holder A 1996. Preventing the merozoite invasion of erythrocyte. In S Hoffman, Malaria vaccine development: a multi-immune response approach, ASM Press, Washington, p. 77-104.
91. Hollingdale MR 1990. Anti-sporozoite antibodies. Bull World Health Organ 68 (Suppl.): 47-51.
92. Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, Arévalo-Herrera M, Herrera S 1997. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus. Ann Trop Med Parasitol 91: 49-60.
93. Inselburg J, Bzik DJ, Li WB, Green KM, Kansopon J, Hahm BK, Bathurst IC, Barr PJ, Rossan RN 1991. Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum. Infect Immun 59: 1247-1250.
94. Jordán-Villegas A, Perdomo AB, Epstein JE, Lopez J, Castellanos A, Manzano MR, Hernandez MA, Soto L, Mendez F, Richie TL, Hoffman SL, Arévalo-Herrera M, Herrera S 2011. Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites. Am J Trop Med Hyg 84: 43-50.
95. Jordán-Villegas A, Zapata JC, Perdomo AB, Quintero GE, Solarte Y, Arévalo-Herrera M, Herrera S 2005. Aotus lemurinus griseimembra monkeys: a suitable model for Plasmodium vivax sporozoite infection. Am J Trop Med Hyg 73: 10-15.
96. Khusmith S, Druilhe P, Gentilini M 1982. Enhanced Plasmodium falciparum merozoite phagocytosis by monocytes from immune individuals. Infect Immun 35: 874-879.
97. King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, Cole-Tobian JL, Mueller I, Chitnis CE 2008. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci USA 105: 8363-8368.
98. Kocken CH, Dubbeld MA, Van Der Wel A, Pronk JT, Waters AP, Langermans JA, Thomas AW 1999. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. Infect Immun 67: 43-49.
99. Kremsner PG, Neifer S, Zotter GM, Bienzle U, Rocha RM, Maracic M, Clavijo P, Nussenzweig RS, Cochrane AH 1992. Prevalence and level of antibodies to the circumsporozoite proteins of human malaria parasites, including a variant of Plasmodium vivax, in the population of two epidemiologically distinct areas in the state of Acre, Brazil. Trans R Soc Trop Med Hyg 86: 23-27.
100. La Raja M 2002. Erythrophagocytosis by peripheral monocytes in Plasmodium falciparum malaria. Haematologica 87: EIM14.
101. Ladeia-Andrade S, Ferreira MU, de Carvalho ME, Curado I, Coura JR 2009. Age-dependent acquisition of protective immunity to malaria in riverine populations of the Amazon Basin of Brazil. Am J Trop Med Hyg 80: 452-459.
102. Lavazec C, Boudin C, Lacroix R, Bonnet S, Diop A, Thiberge S, Boisson B, Tahar R, Bourgouin C 2007. Carboxypeptidases B of Anopheles gambiae as targets for a Plasmodium falciparum transmission-blocking vaccine. Infect Immun 75: 1635-1642.
103. Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, Laumaea A, Schopflin S, Stanisic D, Betuela I, Blood-Zikursh M, Siba P, Felger I, Schofield L, Zimmerman P, Mueller I 2010. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One5: e9047.
104. Lopez JA, Gonzalez JM, Kettner A, Arevalo-Herrera M, Herrera S, Corradin G, Roggero MA 1997. Synthetic polypeptides corresponding to the non-repeat regions from the circumsporozoite protein of Plasmodium falciparum: recognition by human T-cells and immunogenicity in owl monkeys. Ann Trop Med Parasitol 91: 253-265.
105. Lusingu JP, Gesase S, Msham S, Francis F, Lemnge M, Seth M, Sembuche S, Rutta A, Minja D, Segeja MD, Bosomprah S, Cousens S, Noor R, Chilengi R, Druilhe P 2009. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malar J 8: 163.
106. Macdonald G 1951. Community aspects of immunity to malaria. Br Med Bull 8: 33-36.
107. Maestre A, Muskus C, Duque V, Agudelo O, Liu P, Takagi A, Ntumngia FB, Adams JH, Sim KL, Hoffman SL, Corradin G, Velez ID, Wang R 2010. Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC). PLoS One5: e11437.
108. Mahanty S, Saul A, Miller LH 2003. Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J Exp Biol 206: 3781-3788.
109. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A 2005. Phase I vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23: 3131-3138.
110. McCarthy VC, Clyde DF 1977. Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. Exp Parasitol 41: 167-171.
111. McClean CM, Alvarado HG, Neyra V, Llanos-Cuentas A, Vinetz JM 2010. Optimized in vitro production of Plasmodium vivax ookinetes. Am J Trop Med Hyg 83: 1183-1186.
112. McGregor IA 1964. The passive transfer of human malarial immunity. Am J Trop Med Hyg 13: 9.
113. Mendez F, Carrasquilla G, Munoz A 2000. Risk factors associated with malaria infection in an urban setting. Trans R Soc Trop Med Hyg 94: 367-371.
114. Mendis K, Rietveld A, Warsame M, Bosman A, Greenwood B, Wernsdorfer WH 2009. From malaria control to eradication: the WHO perspective. Trop Med Int Health 14: 1-7.
115. Mendis KN, Munesinghe YD, de Silva YN, Keragalla I, Carter R 1987. Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivax in humans. Infect Immun 55: 369-372.
116. Michon PA, Arevalo-Herrera M, Fraser T, Herrera S, Adams JH 1998. Serologic responses to recombinant Plasmodium vivax Duffy binding protein in a Colombian village. Am J Trop Med Hyg 59: 597-599.
117. Miller LH, Howard RJ, Carter R, Good MF, Nussenzweig V, Nussenzweig RS 1986. Research toward malaria vaccines. Science 234: 1349-1356.
118. Montoya E, Moro J, Gózalo A, Samaméb H 1994. Reproduccion de Aotus vociferans (primates cebidae) en cautiverio. Investigaciones Pecuarias 7: 122-126.
119. Moorthy V, Hill AV 2002. Malaria vaccines. Br Med Bull 62: 59-72.
120. Moreira CK, Marrelli MT, Jacobs-Lorena M 2004. Gene expression in Plasmodium: from gametocytes to sporozoites. Int J Parasitol 34: 1431-1440.
121. Moreno A, Caro-Aguilar I, Yazdani SS, Shakri AR, Lapp S, Strobert E, McClure H, Chitnis CE, Galinski MR 2008. Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques. Vaccine 26: 4338-4344.
122. Mota J, Coreno O, Cochrane AH, Ramos C 1996. Prevalence of antibodies to the repeat epitope of the circumsporozoite protein of Plasmodium vivax in San Luis Potosi, Mexico. Arch Med Res 27: 233-236.
123. Mufalo BC, Gentil F, Bargieri DY, Costa FT, Rodrigues MM, Soares IS 2008. Plasmodium vivax apical membrane antigen-1: comparative recognition of different domains by antibodies induced during natural human infection. Microbes Infect 10: 1266-1273.
124. Najera J, Gonzalez-Silva M, Alonso P 2011. Some lessons for the future from the global malaria eradication programme (1955-1969). PLoS Medicine 8: e1000412.
125. Nussenzweig V 1984. Synthetic peptides and malaria surface antigens. Ann Sclavo Collana Monogr 1: 187-189.
126. Nussenzweig V, Nussenzweig RS 1989. Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol 45: 283-334.
127. Oliveira-Ferreira J, Lacerda MV, Brasil P, Ladislau JL, Tauil PL, Daniel-Ribeiro CT 2010. Malaria in Brazil: an overview. Malar J 9: 115.
128. Oliveira-Ferreira J, Pratt-Riccio LR, Arruda M, Santos F, Ribeiro CT, Goldberg AC, Banic DM 2004. HLA class II and antibody responses to circumsporozoite protein repeats of P. vivax (VK210, VK247 and P. vivax-like) in individuals naturally exposed to malaria. Acta Trop 92: 63-69.
129. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois MC, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K, Riley EM, von Seidlein L, Bejon P 2011. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 11: 102-109.
130. Olugbile S, Habel C, Servis C, Spertini F, Verdini A, Corradin G 2010. Malaria vaccines - The long synthetic peptide approach: technical and conceptual advancements. Curr Opin Mol Ther 12: 64-76.
131. Osorio L, Todd J, Bradley D 2004. Absence of asymptomatic malaria in school children of Quibdo, Choco. Biomedica 24: 13-19.
132. Perlaza BL, Sauzet JP, Balde AT, Brahimi K, Tall A, Corradin G, Druilhe P 2001. Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice. Eur J Immunol 31: 2200-2209.
133. Ponnudurai T, Lensen AHW, Gemert GJA V, Bensink MPE, Bolmer M, Meuwissen JHET 1989. Sporozoite load of mosquitoes infected with Plasmodium falciparum. Trans R Soc Trop Med Hyg 83: 67-70.
134. Ponnudurai T, Meuwissen JH, Leeuwenberg AD, Verhave JP, Lensen AH 1982. The production of mature gametocytes of Plasmodium falciparum in continuous cultures of different isolates infective to mosquitoes. Trans R Soc Trop Med Hyg 76: 242-250.
135. Ramsey J, Salinas E, Rodriguez M 1996. Acquired transmission-blocking immunity to Plasmodium vivax in a population of southern coastal Mexico. Am J Trop Med Hyg 54: 458-463.
136. Richie TL, Saul A 2002. Progress and challenges for malaria vaccines. Nature 415: 694-701.
137. Riley EM, Wahl S, Perkins DJ, Schofield L 2006. Regulating immunity to malaria. Parasite Immunol 28: 35-49.
138. Rodrigues MH, Cunha MG, Machado RL, Ferreira OC, Jr., Rodrigues MM, Soares IS 2003. Serological detection of Plasmodium vivax malaria using recombinant proteins corresponding to the 19-kDa C-terminal region of the merozoite surface protein-1. Malar J 2: 39.
139. Rodrigues MM, Cordey AS, Arreaza G, Corradin G, Romero P, Maryanski JL, Nussenzweig RS, Zavala F 1991. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol 3: 579-585.
140. Rogers WO, Gowda K, Hoffman SL 1999. Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens. Vaccine 17: 3136-3144.
141. Rossan RN, Young MD, Baerg DC 1975. Chemotherapy of Plasmodium vivax in Saimiri and Aotus models. Am J Trop Med Hyg 24: 168-173.
142. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P 1991. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45: 297-308.
143. Salas ML, Romero JF, Solarte Y, Olano V, Herrera MA, Herrera S 1994. Development of sporogonic cycle of Plasmodium vivax in experimentally infected Anopheles albimanus mosquitoes. Mem Inst Oswaldo Cruz 89 (Suppl. II): 115-119.
144. Sattabongkot J, Maneechai N, Phunkitchar V, Eikarat N, Khuntirat B, Sirichaisinthop J, Burge R, Coleman RE 2003. Comparison of artificial membrane feeding with direct skin feeding to estimate the infectiousness of Plasmodium vivax gametocyte carriers to mosquitoes. Am J Trop Med Hyg 69: 529-535.
145. Sattabongkot J, Maneechai N, Rosenberg R 1991. Plasmodium vivax: gametocyte infectivity of naturally infected Thai adults. Parasitology 102: 27-31.
146. Scheller LF, Azad AF 1995. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Natl Acad Sci USA 92: 4066-4068.
147. ISM2015 2010. [homepage on the Internet]. Panamá: Iniciativa Salud Mesoamérica 2015. Available from: www.sm2015.org/es/salud-mesoamerica-2015/salud-mesoamerica-2015-inicio,1904.html.
148. Soares IS, Levitus G, Souza JM, Del Portillo HA, Rodrigues MM 1997. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect Immun 65: 1606-1614.
149. Soares IS, Rodrigues MM 2002. Immunogenic properties of the Plasmodium vivax vaccine candidate MSP1(19) expressed as a secreted non-glycosylated polypeptide from Pichia pastoris. Parasitology 124: 237-246.
150. Solarte Y, Manzano MR, Rocha L, Hurtado H, James MA, Arevalo-Herrera M, Herrera S 2011. Plasmodium vivax sporozoite production in Anopheles albimanus mosquitoes for vaccine clinical trials. Am J Trop Med Hyg 84: 28-34.
151. Souza-Silva FA, da Silva-Nunes M, Sanchez BA, Ceravolo IP, Malafronte RS, Brito CF, Ferreira MU, Carvalho LH 2010. Naturally acquired antibodies to Plasmodium vivax Duffy-binding protein (DBP) in Brazilian Amazon. Am J Trop Med Hyg 82: 185-193.
152. Storti-Melo LM, Souza-Neiras WC, Cassiano GC, Taveira LC, Cordeiro AJ, Couto VS, Povoa MM, Cunha MG, Echeverry DM, Rossit AR, Arévalo-Herrera M, Herrera S, Machado RL 2011. Evaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil. Am J Trop Med Hyg 84: 58-63.
153. Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, Kaslow DC, Robinson R, Long CA, Miller LH 2001. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun 69: 1536-1546.
154. Stowers AW, Miller LH 2001. Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? Trends Parasitol 17: 415-419.
155. Suarez-Mutis MC, Cuervo P, Leoratti FM, Moraes-Avila SL, Ferreira AW, Fernandes O, Coura JR 2007. Cross sectional study reveals a high percentage of asymptomatic Plasmodium vivax infection in the Amazon Rio Negro area, Brazil. Rev Inst Med Trop Sao Paulo 49: 159-164.
156. Sultan AA, Thathy V, Frevert U, Robson KJ, Crisanti A, Nussenzweig V, Nussenzweig RS, Menard R 1997. TRAP is necessary for gliding motility and infectivity of Plasmodium sporozoites. Cell 90: 511-522.
157. Takeo S, Hisamori D, Matsuda S, Vinetz J, Sattabongkot J, Tsuboi T 2009. Enzymatic characterization of the Plasmodium vivax chitinase, a potential malaria transmission-blocking target. Parasitol Int 58: 243-248.
158. Taylor-Robinson AW 2010. Regulation of immunity to Plasmodium: implications from mouse models for blood stage malaria vaccine design. Exp Parasitol 126: 406-414.
159. Templeton TJ, Kaslow DC 1997. Cloning and cross-species comparison of the thrombospondin-related anonymous protein (TRAP) gene from Plasmodium knowlesi, Plasmodium vivax and Plasmodium gallinaceum. Mol Biochem Parasitol 84: 13-24.
160. Terrientes ZI, Kramer K, Herrera MA, Chang SP 1994. Naturally acquired antibodies against the major merozoite surface coat protein (MSP-1) of Plasmodium falciparum acquired by residents in an endemic area of Colombia. Mem Inst Oswaldo Cruz (Suppl. II) 89: 55-61.
161. Toure YT, Doumbo O, Toure A, Bagayoko M, Diallo M, Dolo A, Vernick KD, Keister DB, Muratova O, Kaslow DC 1998. Gametocyte infectivity by direct mosquito feeds in an area of seasonal malaria transmission: implications for Bancoumana, Mali, as a transmission-blocking vaccine site. Am J Trop Med Hyg 59: 481-486.
162. Trager W, Jensen JB 1976. Human malaria parasites in continuous culture. Science 193: 673-675.
163. Tsuboi T, Kaslow DC, Gozar MM, Tachibana M, Cao YM, Torii M 1998. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol Med 4: 772-782.
164. Tsuboi T, Tachibana M, Kaneko O, Torii M 2003. Transmission-blocking vaccine of vivax malaria. Parasitol Int 52: 1-11.
165. Valderrama-Aguirre A, Quintero G, Gómez A, Castellanos A, Pérez Y, Méndez F, Arévalo-Herrera M, Herrera S 2005. Antigenicity, immunogenicity and protective efficacy of Plasmodium vivax MSP1 Pv200L: a potential malaria vaccine subunit. Am J Trop Med Hyg 73: 16-24.
166. Van den Eede P, Soto-Calle VE, Delgado C, Gamboa D, Grande T, Rodriguez H, Llanos-Cuentas A, Anne J, D'Alessandro U, Erhart A 2011. Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study. PLoS One 6: e16257.
167. Villard V, Agak GW, Frank G, Jafarshad A, Servis C, Nebie I, Sirima SB, Felger I, Arévalo-Herrera M, Herrera S, Heitz F, Backer V, Druilhe P, Kajava AV, Corradin G 2007. Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PloS One 2: e645.
168. Wang R, Arévalo-Herrera M, Gardner MJ, Bonelo A, Carlton JM, Gomez A, Vera O, Soto L, Vergara J, Bidwell SL, Domingo A, Fraser CM, Herrera S 2005. Immune responses to Plasmodium vivax pre-erythrocytic stage antigens in naturally exposed Duffy-negative humans: a potential model for identification of liver-stage antigens. Eur J Immunol 35: 1859-1868.
169. Westenberger SJ, McClean CM, Chattopadhyay R, Dharia NV, Carlton JM, Barnwell JW, Collins WE, Hoffman SL, Zhou Y, Vinetz JM, Winzeler EA 2010. A systems-based analysis of Plasmodium vivax lifecycle transcription from human to mosquito. PLoS Negl Trop Dis 4: e653.
170. WHO - World Health Organization 1988. Role of non-human primates in malaria vaccine development: memorandum from a WHO meeting. Bull World Health Organ 66: 719-728.
171. WHO - World Health Organization 2010. World malaria report: 2010. Available from: www.who.int/malaria/world_malaria_report_2010/en/index.html.
172. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP 2008. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PloS One3: e2636.
173. Yazdani SS, Shakri AR, Mukherjee P, Baniwal SK, Chitnis CE 2004. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy-binding protein. Vaccine 22: 3727-3737.
174. Yeom JS, Kim ES, Lim KJ, Oh JH, Sohn MJ, Yoo SB, Kim E, Bae I, Jung YJ, Park JW 2008. Naturally acquired IgM antibody response to the C-terminal region of the merozoite surface protein 1 of Plasmodium vivax in Korea: use for serodiagnosis of vivax malaria. J Parasitol 94: 1410-1414.
175. Young MD, Porter JA, Jr., Johnson CM 1966. Plasmodium vivax transmitted from man to monkey to man. Science 153: 1006-1007.
176. Yount EH, Jr, Coggeshall LT 1949. Status of immunity following cure of recurrent vivax malaria. Am J Trop Med Hyg 29: 701-705.